Keyphrases
Neuroendocrine Neoplasms
90%
64Cu-DOTATATE
60%
DOTATATE PET
60%
Gallium-68
51%
Positron Emission Tomography-computed Tomography (PET-CT)
51%
NODAGA
37%
Positron Emission Tomography
31%
Lesion Detection
21%
Prospective Phase II Study
20%
PET Imaging
20%
Phase II Trial
20%
AE105
20%
Soluble Urokinase Plasminogen Activator Receptor (suPAR)
20%
Progression-free Survival
18%
SUVmax
15%
Integrin
13%
Image Quality Detection
13%
After Injection
13%
Artificial Intelligence
12%
Receptor Targets
12%
Angiogenesis
12%
Lesion number
12%
Tumor
11%
Overall Survival
11%
DOTATATE
11%
Prostate Cancer
11%
PET Image
11%
First-in-human
10%
Chronic Myocardial Infarction
10%
Active Sites
10%
Peptide Targeting
10%
Detection Efficiency
10%
Porcine Model
10%
Dose Reduction
10%
C(RGDyK)
10%
Tissue Factor
10%
Primary Cancer
10%
18F-labeled
10%
PET-MRI
10%
Metastatic Cancer
10%
Companion Diagnostics
10%
Receptor-targeted Therapy
10%
Tumor Segmentation
10%
Denoising
10%
Detection Accuracy
10%
Gastrin-releasing Peptide Receptor (GRPr)
10%
United States
10%
Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
10%
Total Tumor Volume
10%
Tumor Delineation
10%
Medicine and Dentistry
Neuroendocrine Tumor
100%
Copper 64
80%
Positron Emission Tomography-Computed Tomography
56%
Neoplasm
55%
Positron Emission Tomography
52%
Positron Emission Tomography
52%
Gallium 68
34%
Prognostication
31%
Phase II Trials
20%
Urokinase Receptor
20%
Progression Free Survival
16%
Diagnosis
16%
Image Quality
15%
Radioactive Tracer
14%
Malignant Neoplasm
14%
Integrin
13%
Somatostatin Receptor
12%
Metastatic Carcinoma
12%
Targeted Therapy
12%
Angiogenesis
11%
Prostate Cancer
11%
Primary Tumor
11%
Overall Survival
10%
Fluorine-18
10%
Factor VII
10%
Drug Dose Reduction
10%
Low Drug Dose
10%
Gastrin Releasing Peptide Receptor
10%
Myocardial Infarction
10%
Thromboplastin
10%
Prostatectomy
10%
Glioblastoma
10%
Patient Referral
10%
Prostate Specific Antigen
8%
Infarction
6%
False Positive Result
6%
Myocardium
6%
Disease
5%
Pharmacology, Toxicology and Pharmaceutical Science
Neuroendocrine Tumor
52%
Copper 64
40%
Neoplasm
36%
Gallium 68
33%
Malignant Neoplasm
14%
Integrin
13%
Tracer
12%
Prostate Cancer
11%
Metastasis
11%
Fluorine 18
10%
Satoreotide Trizoxetan
10%
Primary Tumor
10%
Blood Clotting Factor 7
10%
Porcine Model
10%
Gastrin Releasing Peptide Receptor
10%
Phase II Trials
10%
Thromboplastin
10%
Heart Infarction
10%
Gastroenteropancreatic Neuroendocrine Tumor
10%
Prostate Specific Antigen
10%
Preclinical Study
10%
Urokinase Receptor
10%
Glioblastoma
10%
Polyethylene Terephthalate
10%
Somatostatin Receptor
7%
Infarction
6%
Antigen
5%
